OSR Holdings, Inc.

OSR Holdings, Inc.

OSRHW
OSR Holdings, Inc.US flagNASDAQ Global Market
0.04
USD
+0.00
- -
11.42MMarket Cap
OSR Holdings, Inc.
OSRHW
(NASDAQ Global Market)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
4
3
3
Sales/Revenue/Turnover
- -
- -
-331.2
-631.01
-726.07
Operating Margin (%)
- -
10
10
9
9
Depreciation Expense
1
- -
-10
-18
-10
Net Income, GAAP
- -
57.25
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-292.58
-619.82
-363.3
Profit Margin (%)
-1
-2
-1
-14
-15
Working Capital
- -
562
1
- -
- -
LT Debt
99
33
143
127
127
Total Equity
- -
-0.12
- -
- -
- -
Return on Invested Capital (%)
- -
0.07
- -
- -
- -
Return on Capital (%)
- -
2.17
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
27
33
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3
3
3
Cash, Cash Equivalents & STI
2
2
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
15
17
18
Payables & Accruals
9
9
10
ST Debt
4
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-11.29%
Free Cash Flow
- -
- -
143.55%
Net Income, GAAP
- -
- -
74.37%
Sales/Revenue/Turnover
- -
- -
-17.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
-3
4
2025
1
1
1
- -
3
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
OSR Holdings, Inc. is a global healthcare holding company founded to accelerate healthcare innovation, headquartered in Bellevue, Washington, and publicly listed on NASDAQ since 2025. The company operates a diversified, hub-and-spoke portfolio of subsidiaries specializing in immuno-oncology, regenerative biologics, and medical device technologies. Its core products and services include development of oral T-cell activation therapies targeting tumor vasculature; design-augmented biologics aimed at treating age-related and degenerative diseases, such as DRT-102 for spinal fusion and DRT-101 for osteoarthritis; and the distribution of neurovascular intervention medical devices and noninvasive glucose monitoring systems. OSR Holdings leverages a global network across the United States, Europe, and South Korea to identify and develop transformative healthcare solutions with an emphasis on rigorous science and patient-centered innovation. The company aims to simplify healthcare by centralizing expertise and resources, enabling subsidiary companies to work with agility and focus on high-impact treatments. Its industrial segments encompass biomedical innovation, wellness therapies, and medical systems distribution, serving patient populations worldwide. Recent major developments include OSR Holdings’ strategic roadmap to launch a $50 million security token offering (STO) under Regulation D in the second half of 2025 as part of a blockchain-based capital strategy. This offering complements an $80 million equity line of credit from White Lion GBM Innovation Fund, supporting the company’s goal to build a $100 million reserve in Bitcoin and USDT. Additionally, OSR Holdings continues to pursue partnerships, including term sheet updates with BCM Europe to extend oncology asset licensing, and operational adjustments toward integrating decentralized finance with healthcare innovation. These initiatives reflect significant expansion in the company’s financial and strategic positioning within the biomedical and crypto-healthcare sectors. Overall, OSR Holdings stands as a multi-platform healthcare innovator focused on developing and commercializing novel immunotherapies, biologics, and medical devices while expanding its financial strategies through digital asset integration and global partnerships. It maintains a diversified geographic footprint with operations in the United States, Europe, and Korea, aiming to improve healthcare outcomes and accessibility on a global scale.